Delving into the Latest Updates on Medeno Medical Technology Group Co., Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Neoplasms

Other Diseases

Peptide Conjugate Radionuclide

Therapeutic radiopharmaceuticals

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Nervous System Diseases	1
Hemic and Lymphatic Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Therapeutic radiopharmaceuticals	2
Chemical drugs	1
Peptide Conjugate Radionuclide	1

Top 5 Target	Count

SSTR2(Somatostatin receptor 2)	1

The main purpose of the study is to evaluate the safety and efficacy of MDN-001 injection(Yttrium-90 Microsphere Injection)in the treatment of unresectable hepatocellular carcinoma. Other purposes of this study include assessment of the effect of treatment on overall survival, the length of time it takes for the disease to worsen, if and how the treatment affects the patient's quality of life, and if and how the cancer responds to the treatment.

Start Date04 Aug 2025

Sponsor / Collaborator

Suzhou Medinuoyi Medical Technology Co., Ltd.

CTR20252718

/ Not yet recruitingPhase 1

一项评价 MDN-001 注射液单次给药治疗不可切除的原发性肝癌的安全性与有效性的多中心、开放、单臂 I/II 期临床研究

[Translation] A multicenter, open-label, single-arm Phase I/II clinical study to evaluate the safety and efficacy of a single dose of MDN-001 injection in the treatment of unresectable primary liver cancer

评价MDN-001注射液治疗不可切除的原发性肝癌的安全性与有效性。

[Translation]

To evaluate the safety and efficacy of MDN-001 injection in the treatment of unresectable primary liver cancer.

Start Date-

Sponsor / Collaborator

Suzhou Medinuoyi Medical Technology Co., Ltd.

CTR20252740

/ Not yet recruitingPhase 3

一项比较镥[177Lu]氧奥曲肽注射液与长效奥曲肽在不可手术切除或转移性、生长抑素受体阳性的成人胃肠胰神经内分泌瘤受试者中的有效性和安全性的多中心、随机、开放、平行对照 III 期临床试验

[Translation] A multicenter, randomized, open-label, parallel-controlled phase III clinical trial comparing the efficacy and safety of lutetium [177Lu]oxyoctreotide injection with long-acting octreotide in adult subjects with unresectable or metastatic, somatostatin receptor-positive gastrointestinal pancreatic neuroendocrine tumors

主要目的：评估镥[177Lu]氧奥曲肽注射液对比高剂量长效奥曲肽，在不可手术切除或转移性、生长抑素受体阳性的成人胃肠胰神经内分泌瘤受试者中的有效性。次要目的：评估镥[177Lu]氧奥曲肽注射液对比高剂量长效奥曲肽，在不可手术切除或转移性、生长抑素受体阳性的成人胃肠胰神经内分泌瘤受试者中的安全性；评估镥[177Lu]氧奥曲肽注射液的药代动力学和辐射剂量学特征。

[Translation]

Primary objective: To evaluate the efficacy of lutetium [177Lu] oxyoctreotide injection versus high-dose long-acting octreotide in adult subjects with unresectable or metastatic, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Secondary objectives: To evaluate the safety of lutetium [177Lu] oxyoctreotide injection versus high-dose long-acting octreotide in adult subjects with unresectable or metastatic, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors; To evaluate the pharmacokinetics and radiation dosimetry characteristics of lutetium [177Lu] oxyoctreotide injection.

Start Date-

Sponsor / Collaborator

Medeno Medical Technology Group Co., Ltd.

[+1]

100 Clinical Results associated with Medeno Medical Technology Group Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Medeno Medical Technology Group Co., Ltd.

Login to view more data

100 Deals associated with Medeno Medical Technology Group Co., Ltd.

Login to view more data

100 Translational Medicine associated with Medeno Medical Technology Group Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Apr 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Phase 3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Lutetium Dotatate LU-177 ( SSTR2 )	SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor More	Phase 3
SIR-Spheres	Unresectable Hepatocellular Carcinoma More	Phase 1